Patient Profile
- Sex / Age:
- Female, 54 years
- Height / Weight:
- 164 cm / 72 kg (BMI 26.8)
- Reported symptoms:
- Pruritus (3 months), fatigue, occasional pale stools
- Medications:
- Levothyroxine 75 mcg, oral contraceptive (recent discontinuation)
- Risk factors:
- Family history of autoimmune disease (mother — Sjögren's), no alcohol, non-smoker
Summary Overview
Liver function panel with synthetic markers and platelet count. 9 parameters analyzed; 5 outside reference range. Pattern is dominantly cholestatic with mild synthetic dysfunction — clinical picture warrants further autoimmune and obstructive workup.
Calculated Indices
- R-value:
- 1.6 → Cholestatic pattern (R ≤ 2) [Kwo PY, Am J Gastroenterol 2017]
- AST:ALT ratio:
- 0.78 (low; not suggestive of alcohol-related injury)
- APRI:
- 0.42 (low fibrosis probability) [Sterling RK, Hepatology 2006]
- FIB-4:
- 1.21 (low; <1.45 cutoff) [Shah AG, Hepatology 2009]
Detailed Parameter Analysis
Differential Diagnosis — Conditions to Discuss with Your Physician
-
Primary Biliary Cholangitis (PBC)High
Middle-aged woman, isolated cholestatic biochemistry, pruritus, family history of autoimmunity. ALP >1.5× ULN with positive AMA confirms diagnosis in >90% of cases [Lindor KD et al., Hepatology 2019 — AASLD Guidelines]. Recommend AMA, IgM, and ANA testing.
-
Drug-induced cholestasisModerate
Recent oral contraceptive discontinuation should be reviewed for temporal relationship. Levothyroxine is rarely cholestatic. Estrogens can induce cholestasis particularly in genetically susceptible women.
-
Primary Sclerosing Cholangitis (PSC)Low–Moderate
Typically male predominance and inflammatory bowel disease association; less likely here but cannot be excluded without imaging (MRCP recommended) [Chapman R, Hepatology 2010].
-
Extrahepatic biliary obstructionLow
Pale stools and conjugated hyperbilirubinemia are concerning, but chronicity (3 months) and degree of ALP elevation favor intrahepatic etiology. Abdominal ultrasound is mandatory to exclude.
-
Autoimmune Hepatitis with cholestatic features (overlap)Low
Mild ALT elevation could represent overlap syndrome. ANA, ASMA, and IgG levels would clarify [EASL AIH Guidelines 2015].
Analytical Summary & Recommendations
Clinical pattern
Dominant cholestatic injury pattern (R-value 1.6) with marked ALP and GGT elevation, mild conjugated hyperbilirubinemia, and borderline synthetic dysfunction. Demographic and clinical context (54-year-old woman, autoimmune family history, pruritus) is highly suggestive of an autoimmune cholestatic process — primary biliary cholangitis being the leading consideration.
Recommended next investigations
- Autoimmune serology: AMA (anti-mitochondrial antibody), IgM, ANA, ASMA, IgG
- Imaging: Abdominal ultrasound (first-line); MRCP if biliary tree assessment needed [EASL 2017]
- Viral hepatitis screen: HBsAg, anti-HCV (rule out concurrent disease)
- Bile acid quantification (correlates with pruritus severity)
- Iron studies and ceruloplasmin to exclude metabolic liver disease
- Vitamin D, calcium — chronic cholestasis impairs fat-soluble vitamin absorption
Lifestyle & symptom management
- Symptomatic itch management (cool baths, fragrance-free moisturizers); discuss pharmacologic options with hepatologist if persistent
- Review all medications (including supplements) for cholestatic potential
- Bone density assessment if PBC confirmed (osteoporosis risk)
Monitoring
- Repeat liver panel + serology in 4–6 weeks
- If PBC confirmed, ALP response to therapy (e.g., UDCA) is the primary monitoring target
- Watch for: deepening jaundice, severe pruritus, easy bruising, ascites, confusion — escalate care if any develop
Key Questions for Your Physician
- Should I be tested for AMA, ANA, IgM, and IgG to evaluate for primary biliary cholangitis?
- Is an abdominal ultrasound or MRCP the appropriate first imaging study given my symptoms?
- Could the recently discontinued oral contraceptive be contributing, and should it be considered in differential?
- What pharmacologic options are available for the pruritus while we identify the cause?
- If PBC is confirmed, when should ursodeoxycholic acid (UDCA) be started?
- Should bone density and fat-soluble vitamin levels be assessed given chronicity of cholestasis?
What This Means for You
Your liver panel shows a cholestatic pattern — meaning bile flow from your liver is partially blocked or impaired. This explains the itching you've been experiencing, which is the classic and most bothersome symptom of this kind of liver involvement.
The most likely cause given your profile — middle-aged woman, family history of autoimmune disease, isolated cholestatic biochemistry — is primary biliary cholangitis (PBC), an autoimmune condition affecting the small bile ducts in the liver. PBC is treatable, and early diagnosis significantly improves long-term outcomes.
Your ability to make proteins and clot is only mildly affected, which is reassuring. Your kidneys and basic blood counts are fine. The signal is concentrated in your bile ducts.
Plan for the next 2–4 weeks: see your physician, get the autoimmune blood tests and abdominal ultrasound listed above, and ask about a hepatology referral. With confirmation, treatment can begin and the itching will typically improve within weeks of starting therapy.
Confidence reflects the clarity of the cholestatic pattern and clinical fit with PBC. Final diagnosis requires confirmatory autoimmune serology and imaging — without these, the high-likelihood differential remains a strong hypothesis rather than confirmed diagnosis.
References
- Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol 2017;112(1):18–35.
- Lindor KD, Bowlus CL, Boyer J, et al. Primary Biliary Cholangitis: 2018 Practice Guidance from the AASLD. Hepatology 2019;69(1):394–419.
- EASL Clinical Practice Guidelines on the management of cholestatic liver diseases. J Hepatol 2017;67(1):145–72.
- Sterling RK, Lissen E, Clumeck N, et al. APRI: a simple noninvasive index. Hepatology 2006;43(6):1317–25.
- Shah AG, et al. FIB-4 — comparison of noninvasive markers of fibrosis in patients with NAFLD. Hepatology 2009;49(2):558–67.
- Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010;51(2):660–78.
- EASL Clinical Practice Guidelines: Autoimmune hepatitis. J Hepatol 2015;63(4):971–1004.